REG - Arecor Therapeutics - TETRIS PHARMA LAUNCHES OGLUO® IN GERMANY

Arecor TherapeuticsAnnouncement

01/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221101:nRSA8076Ea&default-theme=true

RNS Number : 8076E  Arecor Therapeutics PLC  01 November 2022

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

TETRIS PHARMA LAUNCHES OGLUO® IN GERMANY

 

Cambridge, UK, 1 November 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that subsidiary company, Tetris Pharma Ltd has today launched
Ogluo® (glucagon prefilled autoinjector pen) as a treatment for severe
hypoglycaemia in children and adults living with diabetes in Germany.
Germany is a significant diabetes market and represents the first launch of
Ogluo® in the European Union.

 

See full Tetris Pharma announcement below:

 

Tetris Pharma launches Ogluo® in Germany

 

A new treatment option for severe hypoglycaemia for children and adults living
with diabetes

 

Represents Tetris Pharma's first launch in European Union

 

1 November 2022 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a
subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC),
today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in
Germany as a treatment for severe hypoglycaemia in children and adults living
with diabetes.

 

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has
been specifically designed for patients living with diabetes with severe
hypoglycaemia. There are an estimated 6.2 million adults living with diabetes
in Germany (IDF Atlas 10(th) Edition).

 

Ogluo® pricing has today been published in the LAUER-TAXE®, the reference
for all German pharmacies, insurers, and wholesalers. Full prescribing
information can be found here. Today's launch in Germany builds on the
roll-out of Ogluo® in Great Britain. As part of the pan-European
commercialisation programme, Tetris Pharma intends to commercialise Ogluo® in
core European markets. The Company is currently in discussions with various
health authorities across Europe to ensure timely launches in other major
European countries.

 

Prof. Barbara Ludwig, Universitätsklinikum Carl Gustav Carus. Dresden,
commented:

"The risk of severe hypoglycaemia can be frightening for people living with
diabetes, as well as for family, friends and carers. With Ogluo® being made
available in Germany, it gives people living with diabetes another
ready-to-use option."

 

Dr Shafiq Choudhary, Managing Director of Tetris Pharma, commented:

"With the launch of Ogluo® in Germany, Tetris Pharma has achieved a
significant milestone through the commercialisation of our flagship product. A
severe hypoglycaemic event can be very frightening, not only for the patients,
but for those around them who have to act quickly. The launch of Ogluo® means
that patients living with diabetes in Germany who may experience severe
hypoglycaemia will now have a new option to tackle those events. We look
forward to expanding our reach within Europe over the coming months to bring
this new treatment to people living with diabetes."

 

Enquiries:

 

Tetris Pharma

Shafiq Choudhary            +44 (0)1628 337579

 

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage
specialty pharmaceutical company with expertise in registering, marketing,
sales and the distribution of speciality hospital products across the UK and
Europe. Our experienced team has a proven history of building and growing
sales. Having secured distribution rights for already licensed products across
Europe, we have a portfolio of niche injectable products including Ogluo(®),
a ready-to-use glucagon for emergency use to treat hypoglycaemia. We
collaborate with partners to provide patients with effective treatments and
quality healthcare by ensuring we deliver accountability, partnership and
performance.

 

For further information, please visit tetrispharma.com
(http://tetrispharma.com)

 

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700

 Chris Gardner, David Daley, Angela Gray          Email: arecor@consilium-comms.com

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLMBBRTMTIJBMT